Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1

Conditions

Prostatic Neoplasms 19Neoplasms 3Prostatic Neoplasms, Castration-Resistant 2Neoplasm Metastasis 2Metastatic Hormone-sensitive Prostate Cancer 2Metastatic Castration-Resistant Prostate Cancer 2Small Cell Lung Carcinoma 1Recurrence 1Prostate Adenocarcinoma 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Lymphoma, Follicular 1Colorectal Neoplasms 1Castrate Sensitive Prostate Cancer 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Bulbo-Spinal Atrophy, X-Linked 1Bites and Stings 1Advanced Prostate Cancer 1Adenocarcinoma 1

Interventions

Cyclophosphamide 11Rituximab 10Prednisone 8Lenalidomide 8Vincristine 7Doxorubicin 7Bendamustine Hydrochloride 6obinutuzumab 5Magnetic Resonance Spectroscopy 4fludarabine 3Whole-Body Irradiation 3Specimen Handling 3R-CHOP protocol 3Cyclosporine 3Biopsy 3zanubrutinib 2fludarabine phosphate 2Radiotherapy 2Prednisolone 2Peripheral Blood Stem Cell Transplantation 2Oxaliplatin 2Mycophenolic Acid 2Melphalan 2Gemcitabine 2Etoposide 2Cytarabine 2venetoclax 1umbralisib 1treosulfan 1tazemetostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Follicular × enzalutamide × 30 days × Clear all
NCT03460977 2026-06-05

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Pfizer

Phase 1 Recruiting
453 enrolled
LymphoidThoracic

Lymphoma, Follicular, Recurrence, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡